• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

20
3
2
2
1

COUNTRY

1
1
1

CATEGORIES

  • 13
  • 12
  • 5
  • 4
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

17
20
27
47

PUBLISHED

0
3
7
47

PRODUCT TYPE

38
9

Search "Wyeth: Performance, Products, Pipeline and Potential" returned 47 results.

PRODUCT TITLE
Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines - Product Thumbnail Image

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In Times of Crisis, Big Pharma turns to Vaccines

Introduction Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeths...

December 2008
FROM
Small Molecule Kinase Inhibitors - Global Strategic Business Report Small Molecule Kinase Inhibitors - Global Strategic Business Report - Product Thumbnail Image

Small Molecule Kinase Inhibitors - Global Strategic Business Report

This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb,...

July 2009
FROM
Infectious Diseases Vaccine Market Overview Infectious Diseases Vaccine Market Overview - Product Thumbnail Image

Infectious Diseases Vaccine Market Overview

Introduction Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth’s...

October 2010
FROM
The CNS Market Outlook to 2010 The CNS Market Outlook to 2010 - Product Thumbnail Image

The CNS Market Outlook to 2010

Maximize future market opportunity with the help of this NEW report... The traditional markets of depression and schizophrenia will see further product launches in the next few years, however many...

October 2005
FROM
IMS Company Profiles:Wyeth IMS Company Profiles:Wyeth - Product Thumbnail Image

IMS Company Profiles:Wyeth

This Company Profile gives you the authoritative insight into a company at a strategic and local level Each individual profile analyzes the critical components that make up a pharmaceutical company,...

February 2009
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights - Product Thumbnail Image

The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights

Pain continues to present numerous challenges to the biopharmaceutical industry According to the American Academy of Pain Medicine, over 76 million Americans suffer from pain Indeed, pain affects more...

October 2010
FROM
The CNS Outlook to 2007 The CNS Outlook to 2007 - Product Thumbnail Image

The CNS Outlook to 2007

With sales of up to $52bn in 2001, and a growth rate of over 10%, the CNS market represents the second largest therapeutic segment of the pharmaceutical market, and one of the fastest growing. Although...

July 2002
FROM
Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI - Product Thumbnail Image

Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years They enable companies to focus on core competencies such as drug discovery...

March 2009
FROM

Noven Pharmaceuticals, Inc. - Strategic SWOT Analysis Review

Noven Pharmaceuticals, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a...

August 2014
FROM
Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics & Metrics to Improve the Bottom Line Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics & Metrics to Improve the Bottom Line - Product Thumbnail Image

Ensuring Profitable Return-on-Investment (ROI) in Pharmaceutical Marketing: Using Analytics & Metrics to Improve the Bottom Line

This report explains the different methods being used such as ROI, promotional response models, econometrics and predictive algorithms and the pros and cons of the different approaches There are step-by-step...

June 2011

ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review

ImmunoGen, Inc. (IMGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData...

January 2014
FROM
Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships - Product Thumbnail Image

Successful Pharmabiotech Alliance Strategies: Driving Synergies, Avoiding Failure and Managing Relationships

Over the past few years, Business Insights has noted that alliances between pharmaceutical (“pharma”) and biotechnology (“biotech”) companies have become common, with hundreds of relationships currently...

September 2008
FROM
Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review

Immtech Pharmaceuticals, Inc. (IMMP) - Financial and Strategic SWOT Analysis Review Summary Immtech Pharmaceuticals, Inc. (Immtech) is a pharmaceutical company that focuses on the global opportunities...

September 2012
FROM

Pharmaceutical Products of the Future: 50-Company Pipeline Analysis to 2015

What Will The Pharmaceutical Market Look Like in the Next Five Years? In this report, Kalorama has analyzed the late stage R&D pipeline of the 50 top companies in pharmaceuticals -- the companies...

July 2010
FROM
Commercial And Pipeline Insight: HRT For Menopausal Symptoms – A New Class Restores An Old Market Commercial And Pipeline Insight: HRT For Menopausal Symptoms – A New Class Restores An Old Market - Product Thumbnail Image

Commercial And Pipeline Insight: HRT For Menopausal Symptoms – A New Class Restores An Old Market

Introduction In 2007, the market value of HRT for menopausal symptoms saw its first upturn since the Women’s Health initiative (WHI) study results in 2002; highly publicized findings which linked HRT...

April 2008
FROM

Companion Biomarkers in Drug Development

Companion biomarkers are diagnostic tests that are specifically linked to a therapeutic drug either during its development or in the clinic This linkage can be an important component of the drug development...

August 2013
FROM

Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022

Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022 Summary Our pharmaceuticals report, “Torisel (Renal Cell Carcinoma) - Analysis and Forecasts to 2022” provides Torisel sales forecasts...

March 2012
FROM

Anti-Infective Drugs Markets

Six infectious diseases -- pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS -- account for half of all premature deaths worldwide, killing mostly children and young adults,...

October 2010
FROM
Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review - Product Thumbnail Image

Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review

Crucell N.V. (CRXL) - Financial and Strategic SWOT Analysis Review Summary Crucell N.V. (Crucell) is a biopharmaceutical company engaged in developing, producing and marketing products for the treatment...

September 2011
FROM
US Cancer Pain Report US Cancer Pain Report - Product Thumbnail Image

US Cancer Pain Report

The US market for the drug treatment of cancer pain in 2008 is valued at $3 1 billion, according to US Cancer Pain Report The cancer pain market is dominated by opioid drugs, a trend expected to continue...

February 2009
FROM
Loading Indicator